COMPASS Pathways plc — Q1 2024 Form 10-Q
Business context and reporting period
For the three months ended March 31, 2024. COMPASS is a clinical-stage biotechnology company developing investigational COMP360 psilocybin treatment with psychological support, primarily for treatment-resistant depression (TRD). It has no approved products and has generated no revenue.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $24.9 million | $19.0 million |
| General and administrative expense | $13.7 million | $12.8 million |
| Total operating expenses / operating loss | $38.6 million / ($38.6 million) | $31.8 million / ($31.8 million) |
| Net loss | ($35.2 million) | ($24.2 million) |
| Basic and diluted loss per share | ($0.55) | ($0.57) |
| Operating cash used | $20.8 million | $27.7 million |
| Cash and cash equivalents at quarter-end | $262.9 million | $117.1 million |
| Current assets / current liabilities | $295.5 million / $19.4 million | At Dec. 31, 2023: $261.3 million / $19.6 million |
| Long-term debt carrying value | $29.1 million | $28.8 million at Dec. 31, 2023 |
Margins are not meaningful because the company has no revenue. Cash, cash equivalents and restricted cash totaled $263.3 million at quarter-end. Net cash increased $42.6 million, primarily due to $26.2 million of ATM share-sale proceeds and $37.3 million from warrant exercises. The company received $14.6 million of UK R&D tax-credit cash during the quarter.
Material changes versus the prior comparable period
- Net loss widened by $11.0 million. R&D spending rose $5.9 million, principally from COMP360 clinical development and higher personnel costs.
- Operating cash use improved by $6.9 million, largely reflecting working-capital timing, including receipt of the UK tax credit.
- Other income increased to $2.4 million from $0.7 million, while interest expense of $1.1 million arose from the Hercules loan. Foreign exchange moved from a $2.7 million gain to a $0.8 million loss; the R&D tax-credit benefit declined to $3.1 million from $4.3 million.
- Shares outstanding increased from 61.9 million at year-end to 68.3 million at March 31, reflecting ATM issuance, warrant exercises and other share activity.
Outlook, commentary, risks and unusual items
- Management expects existing cash to fund operating expenses and capital requirements into 2026, but cautions that this estimate depends on assumptions that may prove incorrect. Further funding may be needed; additional equity could dilute shareholders.
- COMP005, the first pivotal Phase 3 TRD trial, is expected to report top-line data in Q4 2024. COMP006 results are expected by mid-2025. Both trials use change in MADRS score at week 6 as the primary endpoint. A Phase 2 anorexia nervosa trial continues; enrollment in the Phase 2 PTSD study was complete, and the company reported top-line PTSD data on May 8, 2024, after quarter-end.
- The company expects R&D costs to rise as its Phase 3 program advances. The filing emphasizes clinical, regulatory, manufacturing, controlled-substance scheduling, therapist/site capacity, reimbursement, intellectual-property and financing uncertainties.
- The Hercules facility permits up to $50 million of borrowing: $30 million was funded, with a further $10 million tranche subject to performance milestones and another $10 million subject to lender discretion. The loan matures July 2027; principal payments are scheduled to begin July 2025, subject to possible extensions. A $22.5 million minimum-cash covenant begins July 1, 2024, subject to stated conditions. The company reported compliance as of March 31.
- Of 16.1 million PIPE warrants originally issued, 3.75 million had been exercised for cash by March 31. The remaining 12.32 million could produce up to approximately $122.4 million gross if exercised for cash; exercise is not assured and cashless exercise may yield no proceeds.
- The filing reports no material litigation or material contingency reserves. The company’s co-founders stepped down from the board effective March 29, 2024; a permanent chair search was underway, with the lead independent director serving as interim chair.
Most important facts for investors to verify
- Whether Phase 3 COMP005 data arrive in Q4 2024 and support the expected efficacy and safety profile; also track COMP006 timing and results.
- Whether cash use remains consistent with management’s runway estimate through 2026, including rising trial costs and receipt of future R&D tax credits.
- How many outstanding PIPE warrants are exercised for cash, and the resulting proceeds and dilution.
- Compliance with the Hercules minimum-cash covenant and the conditions for accessing additional loan tranches.
- Regulatory requirements for COMP360, including FDA review, controlled-substance scheduling, and any additional data or safety measures required.
- Whether manufacturing supply, qualified therapists and treatment sites, and future coverage and reimbursement can support development and potential commercialization.